GMP Cytokine Market Set to Grow at 8.4% CAGR to 2031, Led by Bio-Techne, PeproTech, CellGenix Amidst Rising Demand for Immunotherapies and Personalized Medicine.
ByAinvest
Friday, Dec 12, 2025 3:27 pm ET1min read
TECH--
The global GMP cytokine market is expected to grow at an 8.4% CAGR from 2025 to 2031, driven by increasing demand for immunotherapies, adoption of personalized medicine, and focus on cancer research. Key players include Bio-Techne, PeproTech, and CellGenix. Emerging trends include a shift towards personalized medicine, bioprocess optimization, and adoption of advanced analytics and AI. Strategic growth opportunities lie in cell and gene therapy, cancer immunotherapy, and vaccine development.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet